Johnson & Johnson (NYSE:JNJ) Holdings Lifted by Hudock Inc.

Hudock Inc. raised its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 8.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,840 shares of the company’s stock after acquiring an additional 621 shares during the quarter. Hudock Inc.’s holdings in Johnson & Johnson were worth $1,280,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in JNJ. RKL Wealth Management LLC increased its stake in Johnson & Johnson by 2.1% in the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock worth $8,562,000 after purchasing an additional 1,010 shares in the last quarter. Geller Advisors LLC increased its position in shares of Johnson & Johnson by 7.5% in the second quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after acquiring an additional 648 shares in the last quarter. Simon Quick Advisors LLC lifted its position in shares of Johnson & Johnson by 296.9% in the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after acquiring an additional 6,537 shares in the last quarter. Lokken Investment Group LLC boosted its stake in Johnson & Johnson by 1.6% in the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock worth $2,302,000 after purchasing an additional 201 shares during the period. Finally, Keebeck Alpha LP raised its stake in Johnson & Johnson by 13.4% during the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after purchasing an additional 525 shares during the period. Institutional investors and hedge funds own 67.94% of the company’s stock.

Insiders Place Their Bets

In other news, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares in the company, valued at $6,869,966.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the transaction, the vice president now directly owns 40,133 shares of the company’s stock, valued at approximately $6,869,966.94. The disclosure for this sale can be found here. Insiders sold 233,611 shares of company stock valued at $40,960,735 over the last 90 days. 0.35% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

NYSE JNJ opened at $168.31 on Tuesday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock’s 50-day moving average is $176.07 and its two-hundred day moving average is $171.13. The firm has a market cap of $440.04 billion, a P/E ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be issued a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on JNJ. Barclays started coverage on Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 price target on the stock. StockNews.com began coverage on Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Sanford C. Bernstein dropped their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Read More

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.